Skip to main content

What the label lists and what reports show

Tinidazole side effects

Tinidazole's FDA label: “The most common adverse reactions in treated patients (incidence >2%), which were not identified in the trichomoniasis, giardiasis and amebiasis studies, are gastrointestinal: decreased appetite, and flatulence; …” FAERS holds 438 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is nausea (28 reports).

  • Generic listed
  • Boxed warning

Check it at the source: the tinidazole FDA label on DailyMed (effective December 27, 2021, Mission Pharmacal Company); the FDA FAERS public dashboard.

What does the label list?

From the label: adverse reactions

The most common adverse reactions in treated patients (incidence >2%), which were not identified in the trichomoniasis, giardiasis and amebiasis studies, are gastrointestinal: decreased appetite, and flatulence; renal: urinary tract infection, painful urination, and urine abnormality; and other reactions including pelvic pain, vulvo-vaginal discomfort, vaginal odor, menorrhagia, and upper respiratory tract infection [See Clinical Studies (14.5)].

Table 1. Adverse Reactions Summary of Published Reports

Reaction2 g single doseMulti-day dose
GI: Metallic/bitter taste3.7%6.3%
Nausea3.2%4.5%
Anorexia1.5%2.5%
Dyspepsia/cramps/epigastric discomfort1.8%1.4%
Vomiting1.5%0.9%
Constipation0.4%1.4%
CNS: Weakness/fatigue/malaise2.1%1.1%
Dizziness1.1%0.5%
Other: Headache1.3%0.7%

Rows and numbers as the label prints them, under its own column headings (the first rows of a longer table where it runs on). A reaction in a trial table is not necessarily caused by the medicine, and trials differ from everyday use.

From the label: adverse reactions, continued

ADVERSE REACTIONS 6.1 Clinical Studies Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Among 3669 patients treated with a single 2 g dose of tinidazole, in both controlled and uncontrolled trichomoniasis and giardiasis clinical studies, adverse reactions were reported by 11.0% of patients. For multi-day dosing in controlled and uncontrolled amebiasis studies, adverse reactions were reported by 13.8% of 1765 patients. Common (≥ 1% incidence) adverse reactions reported by body system are as follows. (Note: Data described in Table 1 below are pooled from studies with variable designs and safety evaluations.) Other adverse reactions reported with tinidazole include: Central Nervous System: Two serious adverse reactions reported include convulsions and transient peripheral neuropathy including numbness and paresthesia [see Warnings and Precautions (5.1)]. Other CNS reports include vertigo, ataxia, giddiness, insomnia, drowsiness.

Source: FDA drug label, Mission Pharmacal Company, effective December 27, 2021 (SPL set a0d01539-8413-4703-94cc-d221918630a1), via openFDA; the full label on DailyMed

What do FAERS reports show?

438 reports list tinidazole among the medicines taken, each a report of something that happened, not proof the medicine caused it; 20 are coded as a death and 129 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Of the 20 reactions below, 12 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.

The 25 most reported reactions

  • Drug Ineffective (a use or a product term, not a reaction)32
  • Nausea (named in the label)28
  • Off Label Use (a use or a product term, not a reaction)26
  • Pruritus26
  • Headache (named in the label)25
  • Diarrhoea (named in the label)23
  • Vomiting (named in the label)23
  • Pyrexia21
  • Anxiety20
  • Rash (named in the label)20
  • Neuropathy Peripheral19
  • Paraesthesia (named in the label)19
  • Pain17
  • Dizziness (named in the label)15
  • Dyspnoea (named in the label)14
  • Urticaria (named in the label)14
  • Hypoaesthesia13
  • Insomnia (named in the label)13
  • Malaise (named in the label)13
  • Asthenia11
  • Condition Aggravated (a use or a product term, not a reaction)11
  • Fatigue (named in the label)11
  • Treatment Failure (a use or a product term, not a reaction)11
  • Drug Effective For Unapproved Indication (a use or a product term, not a reaction)10
  • Dysgeusia10

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms

What next?

Tinidazole: the full record
label, generics, price, shortages, recalls
Side effects hub
the most reported medicines and reactions